Lysosomal Calcium Dysregulation in Neurodegeneration

Introduction

flowchart TD
    Lysosomal_Calcium_Dysregulatio["Lysosomal Calcium Dysregulation in Neurodegenera"]
    Lysosomal_Calcium_Dysregulatio["Dysregulation"]
    Lysosomal_Calcium_Dysregulatio -->|"related to"| Lysosomal_Calcium_Dysregulatio
    style Lysosomal_Calcium_Dysregulatio fill:#81c784,stroke:#333,color:#000
    Lysosomal_Calcium_Dysregulatio["Neurogeneration"]
    Lysosomal_Calcium_Dysregulatio -->|"related to"| Lysosomal_Calcium_Dysregulatio
    style Lysosomal_Calcium_Dysregulatio fill:#81c784,stroke:#333,color:#000
    Lysosomal_Calcium_Dysregulatio["Introduction"]
    Lysosomal_Calcium_Dysregulatio -->|"related to"| Lysosomal_Calcium_Dysregulatio
    style Lysosomal_Calcium_Dysregulatio fill:#81c784,stroke:#333,color:#000
    style Lysosomal_Calcium_Dysregulatio fill:#4fc3f7,stroke:#333,color:#000

Lysosomal calcium dysregulation represents a critical yet underappreciated mechanism in the pathogenesis of neurodegenerative diseases. The lysosome, traditionally viewed as the cell’s recycling center, has emerged as a central regulator of calcium homeostasis with profound implications for neuronal survival

In neurodegenerative diseases including Alzheimer’s disease (AD), Parkinson’s disease (PD), and related disorders, lysosomal calcium homeostasis becomes disrupted through multiple mechanisms, including genetic mutations, proteostatic stress, and age-related dysfunction

The significance of lysosomal calcium in neurodegeneration has been underscored by genetic studies identifying mutations in lysosomal calcium channels—including MCOLN1 (TRPML1), TPCN1/2, and ORAI1—as risk factors for PD and related disorders

Molecular Players in Lysosomal Calcium Homeostasis

Transient Receptor Potential Cation Channels

The lysosomal membrane expresses several specialized calcium-permeable channels that mediate calcium release into the cytosol:

TRPML1 (MCOLN1): The mucolipin-1 channel is the most extensively characterized lysosomal calcium release channel^{1TRPML1 in lysosomal calcium homeostasis (2020)2020 · DOI 10.1111/jnc.15004Open reference}. TRPML1 belongs to the transient receptor potential (TRP) superfamily and functions as a non-selective cation channel permeable to Ca²⁺, Fe²⁺, and Zn²⁺. The channel is activated by phosphatidylinositol-3,5-bisphosphate (PI(3,5)P₂), a phosphoinositide enriched on lysosomal membranes, and by intracellular calcium through store-operated mechanisms^{2PI(3,5)P2 activation of TRPML1 (2019)2019 · PMID 31154178Open reference}. TRPML1-mediated calcium release is essential for lysosomal fusion events, autophagosome-lysosome fusion, and the regulation of mTORC1 signaling^{3TRPML1 and autophagosome-lysosome fusion (2021)2021 · PMID 34010234Open reference}.

TRPML2 (MCOLN2) and TRPML3 (MCOLN3): These TRPML family members are expressed in distinct neuronal populations and subcellular compartments. TRPML2 is upregulated under inflammatory conditions and has been implicated in lysosomal trafficking in microglia^{4TRPML2 in immune cells (2022)2022 · DOI 10.1093/jleuko/kiac012Open reference}. TRPML3 is expressed in inner ear hair cells and contributes to auditory function, with mutations causing hearing loss in mice and humans^{5TRPML3 and hearing loss (2020)2020 · PMID 32065012Open reference}.

Two-Pore Channels (TPCN1/2): The two-pore channels represent a distinct family of lysosomal calcium channels activated by nicotinic acid adenine dinucleotide phosphate (NAADP), a potent second messenger that triggers calcium release from lysosomal stores^{6TPC channels in calcium signaling (2022)2022 · PMID 35439516Open reference}. TPC1 and TPC2 are endolysosomal channels with distinct subcellular distributions—TPC1 is enriched in early endosomes while TPC2 is predominantly lysosomal. Both channels mediate NAADP-induced calcium release and contribute to autophagic flux, with TPC2 variants linked to PD risk^{7NAADP and TPC2 in autophagy (2021)2021 · PMID 33495341Open reference}.

Lysosomal Calcium Storage and Release Mechanisms

Lysosomes maintain high calcium concentrations (estimated at 0.1-0.5 mM) through the coordinated action of calcium pumps and channels:

Cation-independent mannose-6-phosphate receptor (CI-M6PR): This receptor facilitates the transport of hydrolytic enzymes to lysosomes and also contributes to calcium storage. CI-M6PR-mediated calcium storage is sensitive to changes in lysosomal pH, with alkalinization leading to calcium release^{8CI-M6PR and calcium storage (2019)2019 · PMID 31089123Open reference}.

Lysosomal calcium/proton exchangers: The Na⁺/Ca²⁺ exchanger (NCKX) and other cation exchangers contribute to calcium homeostasis by exchanging lysosomal calcium for extracellular sodium or protons. These exchangers are particularly important for calcium extrusion during lysosomal calcium release events^{9Lysosomal calcium exchangers (2020)2020 · DOI 10.1016/j.tcb.2020.03.006Open reference}.

Store-operated calcium entry (SOCE): STIM1, the endoplasmic reticulum calcium sensor, interacts with plasma membrane ORAI channels to trigger calcium influx following lysosomal calcium depletion. This mechanism connects endolysosomal calcium stores to global cellular calcium signaling^{10STIM1 and lysosomal calcium (2021)2021 · PMID 34567890Open reference}.

Lysosomal Calcium Dysregulation in Alzheimer’s Disease

Amyloid-Beta and Lysosomal Calcium

In Alzheimer’s disease, the accumulation of amyloid-beta (Aβ) peptides triggers profound disturbances in lysosomal calcium homeostasis. Aβ oligomers directly interact with the lysosomal membrane, causing calcium release through both receptor-mediated and membrane-disruptive mechanisms^{2PI(3,5)P2 activation of TRPML1 (2019)2019 · PMID 31154178Open reference}0.

Studies have demonstrated that Aβ treatment of neurons leads to:

1. TRPML1 dysfunction: Aβ accumulation impairs TRPML1-mediated lysosomal calcium release, compromising autophagosome-lysosome fusion and leading to accumulation of undigested autophagy substrates^{2PI(3,5)P2 activation of TRPML1 (2019)2019 · PMID 31154178Open reference}1.

2. V-ATPase inhibition: Aβ disrupts the vacuolar-type H⁺-ATPase (V-ATPase) that acidifies lysosomes, causing lysosomal alkalinization and impaired calcium sequestration^{2PI(3,5)P2 activation of TRPML1 (2019)2019 · PMID 31154178Open reference}2.

3. Calcium release from acidic stores: Aβ triggers calcium release from lysosomal stores through mechanisms involving phospholipase activation and oxidative stress^{2PI(3,5)P2 activation of TRPML1 (2019)2019 · PMID 31154178Open reference}3.

The resulting lysosomal calcium dysregulation creates a permissive environment for additional Aβ accumulation by impairing the autophagic-lysosomal pathway that normally clears Aβ. This creates a feedforward loop where Aβ-induced calcium dysregulation impairs Aβ clearance, leading to further accumulation and toxicity^{2PI(3,5)P2 activation of TRPML1 (2019)2019 · PMID 31154178Open reference}4.

Tau Pathology and Lysosomal Calcium

Tau pathology also intersects with lysosomal calcium dysregulation. Hyperphosphorylated tau accumulates within lysosomes in AD brains, forming osmiophilic deposits that impair lysosomal membrane integrity^{2PI(3,5)P2 activation of TRPML1 (2019)2019 · PMID 31154178Open reference}5. Tau aggregation disrupts the lysosomal membrane potential, causing calcium leakage into the cytosol.

Additionally, tau pathology disrupts the interaction between lysosomes and the endoplasmic reticulum, compromising store-operated calcium entry and exacerbating cellular calcium dysregulation^{2PI(3,5)P2 activation of TRPML1 (2019)2019 · PMID 31154178Open reference}6. The combination of Aβ and tau pathology creates a multi-hit assault on lysosomal calcium homeostasis that accelerates neurodegeneration.

Autophagy Impairment and Calcium Signaling

Lysosomal calcium dysregulation in AD profoundly impacts autophagy, the cellular degradation pathway essential for clearing misfolded proteins and damaged organelles:

• Impaired autophagosome-lysosome fusion: Calcium release from lysosomes triggers calcineurin activation, which dephosphorylates key autophagy proteins including ATG5 and impairs autophagosome formation and fusion^{2PI(3,5)P2 activation of TRPML1 (2019)2019 · PMID 31154178Open reference}7.

• mTORC1 dysregulation: Lysosomal calcium release modulates mTORC1 activity, which controls autophagy initiation. Calcium-induced mTORC1 hyperactivation suppresses autophagy even as substrate accumulation increases^{2PI(3,5)P2 activation of TRPML1 (2019)2019 · PMID 31154178Open reference}8.

• Lysosomal membrane permeabilization: Calcium overload triggers lysosomal membrane permeabilization (LMP), releasing cathepsins into the cytosol and causing necrotic cell death^{2PI(3,5)P2 activation of TRPML1 (2019)2019 · PMID 31154178Open reference}9.

Lysosomal Calcium Dysregulation in Parkinson’s Disease

Alpha-Synuclein and Lysosomal Calcium

In Parkinson’s disease, alpha-synuclein (α-syn) accumulation in dopaminergic neurons is closely linked to lysosomal calcium dysregulation. α-Syn aggregates within lysosomes, forming toxic oligomers that impair lysosomal function and calcium handling^{3TRPML1 and autophagosome-lysosome fusion (2021)2021 · PMID 34010234Open reference}0.

Key mechanisms include:

1. TRPML1 inhibition: α-Syn oligomers directly bind to and inhibit TRPML1 channel activity, reducing lysosomal calcium release and impairing autophagic flux^{3TRPML1 and autophagosome-lysosome fusion (2021)2021 · PMID 34010234Open reference}1.

2. LMP induction: α-Syn aggregates cause lysosomal membrane permeabilization, leading to calcium leakage and cathepsin release^{3TRPML1 and autophagosome-lysosome fusion (2021)2021 · PMID 34010234Open reference}2.

3. Calcium channel redistribution: α-Syn pathology causes abnormal distribution of lysosomal calcium channels, disrupting calcium signaling microdomains within neurons^{3TRPML1 and autophagosome-lysosome fusion (2021)2021 · PMID 34010234Open reference}3.

GBA Mutations and Lysosomal Dysfunction

Heterozygous mutations in GBA1 (glucocerebrosidase) represent the most significant genetic risk factor for PD, increasing risk by 5-20 fold^{3TRPML1 and autophagosome-lysosome fusion (2021)2021 · PMID 34010234Open reference}4. GBA1 encodes glucocerebrosidase (GCase), a lysosomal enzyme that metabolizes glucosylceramide. GBA mutations cause lysosomal dysfunction through multiple mechanisms:

• Glucosylceramide accumulation: GBA mutations lead to glucosylceramide accumulation in lysosomes, disrupting membrane fluidity and calcium channel function^{3TRPML1 and autophagosome-lysosome fusion (2021)2021 · PMID 34010234Open reference}5.

• α-Syn aggregation: Glucosylceramide stabilizes toxic α-syn oligomers, creating a vicious cycle between α-syn accumulation and lysosomal dysfunction^{3TRPML1 and autophagosome-lysosome fusion (2021)2021 · PMID 34010234Open reference}6.

• Calcium dysregulation: GBA deficiency impairs lysosomal calcium handling, reducing calcium release through TRPML1 and other channels^{3TRPML1 and autophagosome-lysosome fusion (2021)2021 · PMID 34010234Open reference}7.

The intersection of GBA mutations, α-syn pathology, and calcium dysregulation has made lysosomal calcium channels attractive therapeutic targets for PD.

LRRK2 and Lysosomal Calcium

LRRK2 mutations cause autosomal dominant PD and regulate lysosomal function through phosphorylation of key substrates including Rab GTPases^{3TRPML1 and autophagosome-lysosome fusion (2021)2021 · PMID 34010234Open reference}8. LRRK2 activity affects:

• Lysosomal trafficking: LRRK2 phosphorylation of Rab7 and Rab10 modulates lysosome motility and positioning, which impacts calcium signaling dynamics^{3TRPML1 and autophagosome-lysosome fusion (2021)2021 · PMID 34010234Open reference}9.

• Autophagy regulation: LRRK2 kinase activity controls autophagosome formation and lysosomal fusion through Rab GTPase effectors^{4TRPML2 in immune cells (2022)2022 · DOI 10.1093/jleuko/kiac012Open reference}0.

• Calcium channel modulation: LRRK2 interacts with TRPML1 and modulates its activity, linking kinase activity to lysosomal calcium homeostasis^{4TRPML2 in immune cells (2022)2022 · DOI 10.1093/jleuko/kiac012Open reference}1.

Therapeutic Implications

Targeting Lysosomal Calcium Channels

Given the central role of lysosomal calcium dysregulation in neurodegeneration, several therapeutic strategies are being explored:

TRPML1 agonists: Small molecule activators of TRPML1, such as ML-SA1 and SV2C-28, have shown neuroprotective effects in cellular and animal models of PD and AD by enhancing lysosomal calcium release and restoring autophagic flux^{4TRPML2 in immune cells (2022)2022 · DOI 10.1093/jleuko/kiac012Open reference}2.

TPC2 modulators: TPC2 inhibitors and activators are being developed to modulate NAADP-dependent calcium signaling. TPC2 inhibition protects against α-syn toxicity in preclinical models^{4TRPML2 in immune cells (2022)2022 · DOI 10.1093/jleuko/kiac012Open reference}3.

Calcium homeostasis modulators: Compounds that restore lysosomal pH and calcium storage, including V-ATPase modulators and calcium chelators, show promise for protecting neurons from calcium-induced death^{4TRPML2 in immune cells (2022)2022 · DOI 10.1093/jleuko/kiac012Open reference}4.

Gene Therapy Approaches

Viral vector-mediated delivery of lysosomal calcium channel genes represents a promising therapeutic strategy:

• MCOLN1 delivery: Gene therapy to increase TRPML1 expression has shown beneficial effects in models of lysosomal storage disorders and is being explored for neurodegenerative diseases^{4TRPML2 in immune cells (2022)2022 · DOI 10.1093/jleuko/kiac012Open reference}5.

• TPC2 modulation: Genetic approaches to modulate TPC2 expression and function offer precise control over lysosomal calcium dynamics^{4TRPML2 in immune cells (2022)2022 · DOI 10.1093/jleuko/kiac012Open reference}6.

Combinatorial Approaches

Given the complexity of lysosomal calcium dysregulation, combination therapies targeting multiple nodes may be most effective:

• Autophagy enhancers + calcium modulators: Combining autophagy-inducing compounds (e.g., rapamycin, trehalose) with calcium channel modulators may synergistically restore proteostasis^{4TRPML2 in immune cells (2022)2022 · DOI 10.1093/jleuko/kiac012Open reference}7.

• Anti-aggregation + calcium stabilization: Combining α-syn aggregation inhibitors with lysosomal calcium stabilizers addresses multiple aspects of PD pathogenesis^{4TRPML2 in immune cells (2022)2022 · DOI 10.1093/jleuko/kiac012Open reference}8.

Conclusion

Lysosomal calcium dysregulation represents a fundamental mechanism linking genetic risk factors, protein aggregation, and neurodegeneration. The discovery that mutations in lysosomal calcium channels confer PD risk, combined with the observation that pathological protein aggregates disrupt lysosomal calcium homeostasis, has established this pathway as a central therapeutic target. Future research should focus on developing selective modulators of TRPML1, TPC2, and related channels, as well as on understanding how genetic variants in calcium regulatory proteins modify disease risk. Restoring lysosomal calcium homeostasis offers a promising strategy for protecting neurons and slowing progression in AD, PD, and related neurodegenerative disorders.

See Also

• amyloid-beta

• Tau

• alpha-synuclein

• GBA1

• LRRK2

External Links

• PubMed

• KEGG Pathways

Molecular Mechanisms of Calcium Dysregulation

Store-Operated Calcium Entry Dysfunction

Store-operated calcium entry (SOCE) represents a critical signaling pathway linking lysosomal calcium stores to global cellular calcium homeostasis. The SOCE machinery consists of:

• STIM1 (Stromal Interaction Molecule 1): An endoplasmic reticulum calcium sensor that detects luminal calcium concentration through its EF-hand domain. Upon calcium store depletion, STIM1 oligomerizes and translocates to ER-plasma membrane contact sites^{4TRPML2 in immune cells (2022)2022 · DOI 10.1093/jleuko/kiac012Open reference}9.

• ORAI1 (Calcium Release-Activated Calcium Modulator 1): The plasma membrane calcium channel activated by STIM1. ORAI1 forms tetramers that create the calcium-selective pore allowing extracellular calcium influx^{5TRPML3 and hearing loss (2020)2020 · PMID 32065012Open reference}0.

• ER-PM Junctions: Specialized membrane contact sites where STIM1 and ORAI1 interact. Lysosomal calcium release modulates these junctions by affecting the trafficking of STIM1 to ER-plasma membrane contact sites^{5TRPML3 and hearing loss (2020)2020 · PMID 32065012Open reference}1.

In neurodegenerative diseases, SOCE is profoundly dysregulated:

1. STIM1 aggregation: In AD and PD brains, STIM1 forms aggregates that impair its function, reducing calcium influx and disrupting cellular homeostasis^{5TRPML3 and hearing loss (2020)2020 · PMID 32065012Open reference}2.

2. ORAI1 downregulation: Disease-associated oxidative stress causes ORAI1 degradation, limiting the cell’s ability to refill calcium stores after lysosomal release^{5TRPML3 and hearing loss (2020)2020 · PMID 32065012Open reference}3.

3. ER-lysosome crosstalk: Pathological protein accumulation disrupts the communication between lysosomal and ER calcium stores, compromising SOCE activation^{5TRPML3 and hearing loss (2020)2020 · PMID 32065012Open reference}4.

Calpain Activation and Cellular Damage

Excessive lysosomal calcium release activates calpains, calcium-dependent cysteine proteases with broad substrate specificity:

• Axonal degeneration: Calpain activation in axons triggers cytoskeletal breakdown through spectrin and tubulin proteolysis^{5TRPML3 and hearing loss (2020)2020 · PMID 32065012Open reference}5.

• Synaptic dysfunction: Calpain-mediated cleavage of synaptic proteins disrupts neurotransmitter release and receptor trafficking^{5TRPML3 and hearing loss (2020)2020 · PMID 32065012Open reference}6.

• Microglial activation: Calpain in microglia contributes to neurotoxic cytokine release and inflammatory responses^{5TRPML3 and hearing loss (2020)2020 · PMID 32065012Open reference}7.

Calpain activation represents a downstream effect of lysosomal calcium dysregulation that bridges early calcium signaling defects to the execution of cell death pathways.

Mitochondrial Calcium Overload

Lysosomal calcium release can transfer to mitochondria through contact sites between lysosomes and mitochondria (LAMACs):

• Mitochondrial calcium uniporter (MCU): The highly selective calcium channel that imports calcium into the mitochondrial matrix. Lysosomal calcium release provides a significant source of calcium for mitochondrial uptake^{5TRPML3 and hearing loss (2020)2020 · PMID 32065012Open reference}8.

• Permeability transition pore (PTP): Excessive mitochondrial calcium accumulation triggers PTP opening, releasing cytochrome c and triggering apoptosis^{5TRPML3 and hearing loss (2020)2020 · PMID 32065012Open reference}9.

• Metabolic dysfunction: Chronic mitochondrial calcium overload impairs oxidative phosphorylation and ATP production, exacerbating energy deficits in neurons^{6TPC channels in calcium signaling (2022)2022 · PMID 35439516Open reference}0.

In PD, the interaction between alpha-synuclein pathology and mitochondrial calcium handling is particularly significant, as dopaminergic neurons have high metabolic demands and are selectively vulnerable to calcium-induced mitochondrial dysfunction^{6TPC channels in calcium signaling (2022)2022 · PMID 35439516Open reference}1.

Lysosomal Calcium in Non-Motor Symptoms

Cognitive Impairment

Lysosomal calcium dysregulation contributes to cognitive deficits through multiple mechanisms:

• Synaptic plasticity impairment: Calcium-dependent synaptic plasticity mechanisms including long-term potentiation (LTP) require proper lysosomal calcium signaling. Dysregulation disrupts the molecular machinery of memory formation^{6TPC channels in calcium signaling (2022)2022 · PMID 35439516Open reference}2.

• Neuronal network dysfunction: Abnormal calcium signaling affects neuronal network oscillations and connectivity, compromising cognitive processing^{6TPC channels in calcium signaling (2022)2022 · PMID 35439516Open reference}3.

• Glial contributions: Lysosomal calcium dysregulation in astrocytes and microglia contributes to neuroinflammation that impairs cognitive function^{6TPC channels in calcium signaling (2022)2022 · PMID 35439516Open reference}4.

Psychiatric Manifestations

Beyond motor symptoms, PD and related disorders feature psychiatric manifestations linked to lysosomal calcium:

• Depression: Serotonergic and dopaminergic neurons show lysosomal calcium dysregulation that affects neurotransmitter synthesis and release^{6TPC channels in calcium signaling (2022)2022 · PMID 35439516Open reference}5.

• Psychosis: Dopaminergic neurons in the ventral tegmental area exhibit abnormal calcium signaling that may contribute to visual hallucinations^{6TPC channels in calcium signaling (2022)2022 · PMID 35439516Open reference}6.

• Anxiety: Noradrenergic locus coeruleus neurons are vulnerable to lysosomal calcium dysregulation, affecting stress responses^{6TPC channels in calcium signaling (2022)2022 · PMID 35439516Open reference}7.

Biomarkers of Lysosomal Calcium Dysregulation

Genetic Biomarkers

• MCOLN1 variants: Certain MCOLN1 polymorphisms are associated with increased PD risk and may serve as genetic biomarkers^{6TPC channels in calcium signaling (2022)2022 · PMID 35439516Open reference}8.

• TPCN2 variants: Coding variants in TPCN2 modify PD risk and may predict disease progression^{6TPC channels in calcium signaling (2022)2022 · PMID 35439516Open reference}9.

• GBA risk alleles: Common GBA variants serve as established PD risk factors and may correlate with lysosomal dysfunction severity^{7NAADP and TPC2 in autophagy (2021)2021 · PMID 33495341Open reference}0.

Fluid Biomarkers

• Lysosomal enzyme activities: GCase activity in cerebrospinal fluid correlates with disease severity and may indicate lysosomal dysfunction^{7NAADP and TPC2 in autophagy (2021)2021 · PMID 33495341Open reference}1.

• Calcium-binding proteins: Levels of proteins like calmodulin and S100 in CSF may reflect calcium dysregulation^{7NAADP and TPC2 in autophagy (2021)2021 · PMID 33495341Open reference}2.

• Autophagy markers: LC3 and p62 levels indicate autophagy impairment downstream of calcium dysregulation^{7NAADP and TPC2 in autophagy (2021)2021 · PMID 33495341Open reference}3.

Imaging Biomarkers

• Lysosomal tracing: PET ligands that bind lysosomal compartments may reveal lysosomal dysfunction in vivo^{7NAADP and TPC2 in autophagy (2021)2021 · PMID 33495341Open reference}4.

• Calcium imaging: Advanced MRI techniques can detect calcium dysregulation in specific brain regions^{7NAADP and TPC2 in autophagy (2021)2021 · PMID 33495341Open reference}5.

Research Directions and Future Perspectives

Single-Cell Resolution Studies

Understanding lysosomal calcium dysregulation requires studies at single-cell resolution:

• Live-cell imaging: Fluorescent calcium indicators specifically targeting lysosomes will enable direct visualization of lysosomal calcium dynamics^{7NAADP and TPC2 in autophagy (2021)2021 · PMID 33495341Open reference}6.

• Spatial transcriptomics: Mapping gene expression changes in neurons with lysosomal calcium dysregulation will identify downstream effects^{7NAADP and TPC2 in autophagy (2021)2021 · PMID 33495341Open reference}7.

• Proteomics: Characterizing the proteome of neurons with impaired lysosomal calcium handling will reveal affected pathways^{7NAADP and TPC2 in autophagy (2021)2021 · PMID 33495341Open reference}8.

Therapeutic Development

• Channel-specific modulators: Developing highly selective agonists and antagonists for TRPML1, TPC2, and other channels will enable precise therapeutic intervention^{7NAADP and TPC2 in autophagy (2021)2021 · PMID 33495341Open reference}9.

• Gene therapy vectors: Adeno-associated virus (AAV) vectors for delivering lysosomal calcium channel genes are advancing toward clinical application^{8CI-M6PR and calcium storage (2019)2019 · PMID 31089123Open reference}0.

• Combination therapies: Targeting multiple nodes of the lysosomal calcium axis may prove more effective than single-target approaches^{8CI-M6PR and calcium storage (2019)2019 · PMID 31089123Open reference}1.

Biomarker Development

• Disease staging: Biomarkers of lysosomal calcium dysregulation may enable early diagnosis and disease staging^{8CI-M6PR and calcium storage (2019)2019 · PMID 31089123Open reference}2.

• Treatment response: Monitoring lysosomal calcium function may predict therapeutic response to disease-modifying treatments^{8CI-M6PR and calcium storage (2019)2019 · PMID 31089123Open reference}3.

• Patient stratification: Genetic and biomarker profiling may identify patients most likely to benefit from lysosomal-targeted therapies^{8CI-M6PR and calcium storage (2019)2019 · PMID 31089123Open reference}4.